| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-115-3-195 |
| P698 | PubMed publication ID | 1905501 |
| P50 | author | David Y. Graham | Q79074636 |
| P2093 | author name string | Agrawal NM | |
| Roth S | |||
| White RH | |||
| Brown JA | |||
| Stromatt SC | |||
| Germain B | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| prevention | Q1717246 | ||
| misoprostol | Q416025 | ||
| P304 | page(s) | 195-200 | |
| P577 | publication date | 1991-08-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial | |
| P478 | volume | 115 |
| Q43297764 | A fixed dose combination of ibuprofen and famotidine |
| Q33183500 | Advances in anti-inflammatory therapy |
| Q77689461 | Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers |
| Q31881373 | Approaches to healing and prophylaxis of nonsteroidal anti-inflammatory drug-associated ulcers |
| Q33697186 | Arthrotec: the evidence speaks for itself. |
| Q31935428 | COX-2 inhibitors in rheumatoid arthritis |
| Q45058341 | Curative and preventive treatment of NSAID-associated gastroduodenal ulcers |
| Q28210656 | Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond |
| Q33813174 | Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications |
| Q34340684 | Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives |
| Q33883996 | Diagnosis and treatment of nonsteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity |
| Q33565994 | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis |
| Q39493657 | Drug treatment of arthritis. Update on conventional and less conventional methods |
| Q42132095 | Effect of sucralfate on aspirin induced mucosal injury and impaired haemostasis in humans |
| Q39034536 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease |
| Q40661010 | Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs |
| Q33567195 | Experience with misoprostol therapy for NSAID gastropathy in children |
| Q40466622 | From peptic ulcer disease to NSAID gastropathy. An evolving nosology. |
| Q40831716 | Future trends in the development of safer nonsteroidal anti-inflammatory drugs |
| Q35192753 | Gastric Adaptation to Nonsteroidal Anti-Inflammatory Drugs in Man |
| Q41331934 | Gastric toxicity of antiplatelet therapy with low-dose aspirin |
| Q40155507 | Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs |
| Q71775383 | Gastrointestinal complications of nonsteroidal antiinflammatory drugs: prophylactic and therapeutic strategies |
| Q77142022 | Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs |
| Q36214082 | Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDS). Rationale and clinical implications |
| Q35613265 | Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness |
| Q33412100 | Guidelines for prevention of NSAID-related ulcer complications |
| Q31881401 | Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs |
| Q70637500 | Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis |
| Q35989849 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled tria |
| Q50627866 | Management of NSAID-induced gastropathy: an economic decision analysis. |
| Q40192153 | Management of NSAID-related gastrointestinal mucosal injury |
| Q28192901 | Management of peptic ulcer disease not related to Helicobacter |
| Q72188612 | Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study |
| Q35448618 | Misoprostol in the prevention of gastroduodenal damage in rheumatology |
| Q33560264 | Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs |
| Q28199428 | Mucosa protective therapy with long-term nonsteroidal antirheumatic drugs |
| Q34475723 | Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum |
| Q45711881 | NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite. |
| Q41331940 | NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus |
| Q74823411 | NSAIDS and gastropathy |
| Q40936877 | NSAIDs, gastrointestinal injury, and cytoprotection |
| Q36514772 | Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis. |
| Q57169425 | Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity |
| Q37986562 | Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. |
| Q41078785 | Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury |
| Q40567516 | Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword |
| Q39403304 | Nonsteroidal antiinflammatory drugs and upper gastrointestinal hemorrhage in an urban hospital |
| Q50956118 | Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. |
| Q39446511 | Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs |
| Q72709071 | Omeprazole ameliorates aspirin-induced gastroduodenal injury |
| Q40594545 | Postsurgical complications in older patients. The role of pharmacological intervention. |
| Q34267128 | Preventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies |
| Q33925273 | Prevention of NSAID-related ulcers |
| Q37893966 | Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors |
| Q33978682 | Prevention of chronic NSAID induced upper gastrointestinal toxicity |
| Q46534922 | Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine |
| Q32065085 | Prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions: a commentary on the new data |
| Q33678334 | Prophylaxis and treatment of NSAID-induced gastroduodenal disorders |
| Q34517173 | Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects |
| Q31795122 | Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs |
| Q33543497 | Recognizing peptic ulcer disease. Keys to clinical and laboratory diagnosis |
| Q35814862 | Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs |
| Q35832877 | Renal effects of peptic ulcer therapy |
| Q40816610 | Rheumatoid arthritis in the aged. Incidence and optimal management |
| Q43837826 | Synthesis and evaluation of a nonsteroidal anti-inflammatory polymeric prodrug for sustained and site-specific delivery |
| Q88787445 | Synthesis and in vivo anti-ulcer evaluation of some novel piperidine linked dihydropyrimidinone derivatives |
| Q34045829 | Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs |
| Q37056770 | Systematic review: ulcer definition in NSAID ulcer prevention trials |
| Q34034067 | The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature |
| Q71213777 | The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone |
| Q33542921 | The use of analgesics in the management of pain in rheumatic diseases |
| Q41482822 | Therapy and prevention of gastric ulcer. |
| Q41526041 | Toxicity of Nonsteroidal Anti-Inflammatory Drugs in the Elderly: Is Advanced Age a Risk Factor? |
| Q74247530 | [Risk of ulcer and its prophylaxis in therapy with non-steroidal antirheumatic drugs] |
Search more.